Roche’s Alecensa shows significant effect over Pfizer’s Xalkori to treat ALK- positive NSCLC

This article was originally published here

A phase III study has revealed that Roche’s Alecensa (alectinib) showed significant effect over Pfizer’s Xalkori (crizotinib) in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply